ReviewInternational journal of molecular sciences2026
Artificial Intelligence-Driven Integration of ECG and Molecular Biomarkers in Pulmonary Embolism.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism (PE) is a serious cardiovascular condition and the third leading cause of cardiovascular mortality worldwide. However, its clinical presentation is often non-specific, making timely detection challenging. Biomarkers are commonly used to support early diagnosis and risk stratification. Molecular biomarkers provide information related to coagulation, inflammation, and cardiac injury. Electrocardiography (ECG) reflects cardiac functional changes caused by right ventricular (RV) stress and dilation secondary to increased pulmonary vascular resistance. Individually, these biomarkers have limited diagnostic accuracy. A promising approach to improving PE management involves integrating multimodal clinical data using Artificial Intelligence (AI). AI-based models can detect subtle patterns in ECG signals and molecular biomarker profiles that may be missed by conventional analysis. Combining these data sources may enhance diagnostic accuracy, refine risk assessment, and support personalized treatment. Despite ongoing challenges, including data quality, interpretability, and ethical considerations, AI-driven integration of ECG and molecular biomarkers represents a significant step forward in PE diagnosis and management. Further validation in large, prospective clinical studies is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.